Merck To Continue Its M&A Spree (MRK, MIL)
Merck (NYSE: MRK) is planning to continue its M&A activities following the conclusion of its $6 billion Millipore (NYSE: MIL) deal. Merck’s (MRK) chief executive officer Karl-Ludwig said, "We have indeed a few ideas. Acquisitions are a part of our strategy." Merck’s focus is to diversify its business. Merck bought Swiss biotech company Soreno for $14 billion in 2007.
He also quashed the charges of making expensive deals. He said, “We will show that we have paid an absolutely fair price for the American firm Millipore (MIL)." Merck is experiencing a gradual decrease in the margins of its liquid crystals unit. The unit is facing tough competition from its Asian rivals.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
